Thubilux Pharma SpA has received a structured loan of US$2.7 million from a leading Italian bank
Tubilux Pharma SpA has successfully raised funds through a structured loan from Cassa Depositi e Prestiti SpA and Banca Intesa San Paolo SpA to support an investment plan for a new production facility which has all the FDA requirements to enter the USA market.
Tubilux Pharma is a leading, privately-held ophthalmic and pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products, with distribution in approximately 30 countries. The firm's customers are large multinational pharmaceutical companies that outsource their production of ophthalmic products to specialized manufactures through medium-term supply contracts (3-5 years).
Oaklins' team in Italy advised Thubilux Pharma SpA in the structuring, negotiation and closing of a long-term debt financing from a leading Italian bank, backed by Cassa Depositi e Prestiti.
Talk to the deal team
Related deals
Hemink Groep has been acquired by Gimv
Gimv has acquired a majority stake in Hemink, a Dutch specialist in real estate renovation and maintenance. This transaction marks a new chapter for Hemink, as it seeks to expand its position as a national leader in sustainable property services through its new partnership with Gimv.
Learn moreThe Providence Projects has been acquired by UKAT Group
Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn more